Author:
Bao Xun,Wu Jianmei,Sanai Nader,Li Jing
Funder
United States National Institute of Health (NIH) Cancer Center
Ben & Catherine Ivy Foundation
Subject
Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry
Reference18 articles.
1. Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2- metastatic breast cancer: a focus on ribociclib;Edessa;Breast Cancer Dove Med. Press (Dove Med Press),2017
2. Targeting CDK4/6 in patients with cancer;Hamilton;Cancer Treat. Rev.,2016
3. Clinical development of CDK4/6 inhibitor for breast cancer;Iwata;Breast Cancer,2018
4. CDK4/6 inhibitors: the mechanism of action may not Be as simple as once thought;Klein;Cancer Cell,2018
5. Cell cycle proteins as promising targets in cancer therapy;Otto;Nat. Rev. Cancer,2017